Ironwood Pharma (IRWD) Tops Q3 EPS by 6c; Trims Cash Burn Outlook
Get Alerts IRWD Hot Sheet
Join SI Premium – FREE
Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $66.1 million versus the consensus estimate of $60.01 million.
Ironwood now expects to use less than $50 million in cash for operations in 2016, down from previous guidance of less than $70 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Vail Resorts (MTN) Reports Certain Ski Season Metrics for the Season-to-Date Period Ended April 14
- Acme United (ACU) Misses Q1 EPS by 20c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!